Scotiabank Raises argenx (NASDAQ:ARGX) Price Target to $408.00

argenx (NASDAQ:ARGX) had its price target raised by Scotiabank from $402.00 to $408.00 in a research report sent to investors on Tuesday, Benzinga reports. Scotiabank currently has a sector perform rating on the stock.

Other analysts also recently issued reports about the stock. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a buy rating to a hold rating in a research report on Wednesday, December 20th. JPMorgan Chase & Co. reduced their price target on shares of argenx from $615.00 to $560.00 and set an overweight rating on the stock in a report on Tuesday, December 5th. Piper Sandler lifted their price target on shares of argenx from $518.00 to $522.00 and gave the company an overweight rating in a report on Friday, January 26th. Wells Fargo & Company lifted their price target on shares of argenx from $472.00 to $478.00 and gave the company an overweight rating in a report on Tuesday, February 20th. Finally, Raymond James reduced their target price on shares of argenx from $580.00 to $520.00 and set a strong-buy rating on the stock in a report on Thursday, December 21st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $530.74.

argenx Trading Down 1.2 %

ARGX opened at $393.72 on Tuesday. argenx has a 1-year low of $327.73 and a 1-year high of $550.76. The company has a market capitalization of $23.35 billion, a PE ratio of -76.60 and a beta of 0.65. The firm’s 50 day simple moving average is $387.95 and its two-hundred day simple moving average is $434.94.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The firm had revenue of $417.84 million for the quarter, compared to the consensus estimate of $378.60 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same quarter in the previous year, the business earned ($0.70) earnings per share. Equities analysts forecast that argenx will post -2.07 earnings per share for the current fiscal year.

Institutional Trading of argenx

Institutional investors have recently bought and sold shares of the stock. Parkside Financial Bank & Trust bought a new stake in argenx in the third quarter worth $28,000. ADAR1 Capital Management LLC bought a new stake in shares of argenx during the fourth quarter worth $27,000. KB Financial Partners LLC lifted its position in shares of argenx by 112.5% during the first quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 45 shares during the last quarter. FNY Investment Advisers LLC bought a new stake in shares of argenx during the fourth quarter worth $38,000. Finally, Nkcfo LLC lifted its position in shares of argenx by 22.1% during the third quarter. Nkcfo LLC now owns 116 shares of the company’s stock worth $57,000 after purchasing an additional 21 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.